Insider Buying: HCW Biologics (NASDAQ:HCWB) CFO Purchases 14,235 Shares of Stock

HCW Biologics Inc. (NASDAQ:HCWB) CFO Rebecca Byam acquired 14,235 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was purchased at an average cost of $1.41 per share, with a total value of $20,071.35. Following the completion of the purchase, the chief financial officer directly owned 57,245 shares of the company’s stock, valued at approximately $80,715.45. This represents a 33.10% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

HCW Biologics Trading Down 26.0%

HCWB traded down $0.68 on Wednesday, hitting $1.94. 3,330,455 shares of the company were exchanged, compared to its average volume of 36,091,248. The firm has a 50-day moving average price of $0.72 and a two-hundred day moving average price of $1.15. The company has a market cap of $13.06 million, a price-to-earnings ratio of -0.21 and a beta of 1.13. HCW Biologics Inc. has a twelve month low of $0.25 and a twelve month high of $8.75.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.81. The business had revenue of $6.54 million during the quarter, compared to analysts’ expectations of $6.54 million. HCW Biologics had a negative return on equity of 486.87% and a negative net margin of 34.73%.

Institutional Trading of HCW Biologics

A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC bought a new stake in HCW Biologics Inc. (NASDAQ:HCWB) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 2.96% of the company’s stock.

Wall Street Analyst Weigh In

HCWB has been the subject of several analyst reports. Wall Street Zen raised HCW Biologics to a “hold” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a research report on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $35.00.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.